 Toxicity immunomodulatory effects autologous bone marrow transplantation hematologic malignancies Autologous bone marrow transplantation ABMT advanced hematologic malignancies high relapse rates lymphokine-activated killer LAK cells non-cross-resistant therapeutic modality relapses ABMT time tumor burden minimal high-dose chemoradiotherapy ABMT patients susceptibility toxicity immunologic responses vivo safety tolerance immunomodulatory effects therapy ABMT continuous intravenous infusion patients days median ABMT acute leukemia lymphoma multiple myeloma Patients induction doses days patients nonescalating maintenance dose days patients mild fever nausea diarrhea and/or skin rash infusions maximum tolerated induction dose dose-limiting toxicities hypotension thrombocytopenia toxicities infusions patients maintenance Postinfusion lymphocytosis patients dose levels doses percentages patients PBMC augmented lysis Daudi induction natural killer LAK effector activities LAK precursor activity patients dose levels therapy regimen ABMT immunomodulatory effects doses studies use LAK cells ABMT attempt relapses advanced hematologic malignancies